Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | c/o Pushor Mitchell LLP 301 - 1665 Ellis Street KELOWNA BC V1Y 2B3 |
Tel: | N/A |
Website: | https://tryptherapeutics.com |
IR: | See website |
Key People | ||
N/A |
Business Overview |
Tryp Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Company's lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The Company's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience. |
Financial Overview |
For the three months ended 30 November 2023, Tryp Therapeutics Inc revenues was not reported. Net loss decreased 29% to C$1.2M. Lower net loss reflects Research and development decrease of 73% to C$260K (expense), Share-based payments decrease of 85% to C$28K (expense), Interest income increase from C$1K to C$3K (income). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $4.13M as of Nov 30, 2023 |
Annual revenue (TTM): | $0.00M as of Nov 30, 2023 |
EBITDA (TTM): | -$4.06M as of Nov 30, 2023 |
Net annual income (TTM): | -$4.79M as of Nov 30, 2023 |
Free cash flow (TTM): | -$3.63M as of Nov 30, 2023 |
Net Debt Last Fiscal Year: | $2.95M as of Nov 30, 2023 |
Shares outstanding: | 96,419,347 as of Nov 30, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |